Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions encompass a wide range of topics related to the article, including mentions of presentations at conferences and recent studies published in relevant journals. For instance, discussions highlight outstanding presentations on metabolic changes associated with intestinal failure by Dr. Yoyo Zhang, and the reduced risk of liver disease associated with alternative lipid emulsions. Phrases like 'congratulations' and 'exceptional presentation' convey a tone of admiration and underscore the ongoing relevance and urgency of these studies in the field.
The overall sentiment reflects moderate agreement with the topics discussed, as many posts acknowledge the importance of current research and findings related to intestinal failure-associated liver disease.
There is a strong indication of interest, as users frequently reference new publications and conferences, demonstrating an eagerness to learn more about IFALD.
While several posts dive into specific findings and presentations, the depth of engagement is moderate, suggesting that while users are engaged, not all discussions delve deeply into technical aspects.
Users perceive high impact in the discussions, with many acknowledging the significance of new research and guidelines in advancing the understanding and management of IFALD.
Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations. https://t.co/qegxtuaHVV
New and open access article in #JPEN: Lipid strategies to prevent intestinal failure–associated liver disease in neonates: A pilot trial. https://t.co/i0dAA3hBpH
Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
#Natural bioactive compounds – the promising candidates for the treatment of intestinal failure-associated #liver disease
Excellent presentations by Drs Park and Alligood from the Warner Lab on intestinal failure associated liver disease after massive small bowel resection! @BradWarnerMD @attaparka @WashUMedPedSurg #ASC2025 #PedSurgBestSurg https://t.co/wXUR5A8NGT
Early signs of liver dysfunction can manifest in various ways, often years before significant issues arise. Understanding these warning signals is essential in preventing severe conditions. This video explores the…
Wut is often a sign of liver overload, particularly in Traditional Chinese Medicine. This video explores the connection between liver health and intestinal failure-associated liver disease (IFALD), emphasizing the…
Traditional lipid emulsions are rich in omega-6 fatty acids (from 100% soybean oil), which promote inflammation and may contribute to parenteral nutrition-associated liver disease (PNALD) or intestinal failure-associated liver disease (IFALD)
Congrats to Katie Huff, MD, MS for presenting her project, "Development of intestinal failure associated liver disease is associated with specific metabolomic and transcriptomic changes in the neonate," at the @ASPEN_nutrition Science and Practice Conference this year! https://t.co/V4gIBKs97j
Just published in the Journal of Parenteral and Enteral Nutrition: "Diagnosis of adult patients with intestinal failure–associated liver disease: A descriptive cross‐sectional study". https://t.co/MCgjbVA4a4
ASPEN President-Elect Dr. Kathleen Gura recently attended the @mespenuae Congress in Dubai. Dr. Gura presented on the use of alternative intravenous lipid emulsions in the NICU & PICU and Pediatric Intestinal Failure Associated Liver Disease. https://t.co/c3w2JRhEUL
Exceptional presentation on intestinal failure associated liver disease by Dr. Yoyo Zhang! @ttsorg #split2025 @StanfordChild https://t.co/dAjAUMKmum
RT @sociedadSEEN:
RT @sociedadSEEN:
RT @abiaadsasha: Parenteral nutrition improves intestinal failure but carries a significant risk of hepatotoxicity. Check out our latest…
RT @abiaadsasha: Parenteral nutrition improves intestinal failure but carries a significant risk of hepatotoxicity. Check out our latest…
Parenteral nutrition improves intestinal failure but carries a significant risk of hepatotoxicity. Check out our latest review on the pathogenesis and management of intestinal failure-associated liver disease. @ThiemeIntl #IFALD #PNALD @RachaKhalafMD https://t.co/m1u5r8J2p9 https://t.co/eQ7Hwk0mjF
Just published in the Journal of Parenteral and Enteral Nutrition: "Intestinal failure–associated liver disease in adult patients with chronic intestinal failure receiving home parenteral nutrition: A descriptive cohort study". https://t.co/TpEgZtXfAL
RT @DrJasmine_MD: Excellent presentations by Drs Park and Alligood from the Warner Lab on intestinal failure associated liver disease after…
RT @DrJasmine_MD: Excellent presentations by Drs Park and Alligood from the Warner Lab on intestinal failure associated liver disease after…
Excellent presentations by Drs Park and Alligood from the Warner Lab on intestinal failure associated liver disease after massive small bowel resection! @BradWarnerMD @attaparka @WashUMedPedSurg #ASC2025 #PedSurgBestSurg https://t.co/wXUR5A8NGT
Just published in the Journal of Parenteral and Enteral Nutrition: "Prediction of chronic severe intestinal failure–associated liver disease by current criteria in adults: A descriptive cohort study". https://t.co/5l7NiLYJAv
RT @PharmacolRes: Check out this interesting review from @PUMS_tweets et al. on the molecular mechanisms underlying hepatoprotective activi…
RT @PharmacolRes: Check out this interesting review from @PUMS_tweets et al. on the molecular mechanisms underlying hepatoprotective activi…
Check out this interesting review from @PUMS_tweets et al. on the molecular mechanisms underlying hepatoprotective activity of lutein in intestinal failure-associated liver disease: https://t.co/lz7gc3Josf #Lutein #Liver #IntestinalFailure #PharmacolRes #openaccess #Research https://t.co/dz10USKiGL
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @Charl0tteRutter: Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
Our next #ClinNutWebinar is on “Intestinal Failure Associated Liver Disease (IFALD)”
RT @TrevorTabone: Grateful to have had a chat with @berkeleydoc @ASPEN_nutrition about 'Parenteral Nutrition Challenges and Considerations…
Grateful to have had a chat with @berkeleydoc @ASPEN_nutrition about 'Parenteral Nutrition Challenges and Considerations with Intestinal Failure-Associated Liver Disease' co-authored with Dr Clare Donnellan and Dr Peter Mooney! https://t.co/qCbbeTbynp
RT @heniek_htw: Overview of intestinal failure-associated liver disease (IFALD). (A) clinical symptoms, (B) disease triggers, (C) treatment…
RT @heniek_htw: Overview of intestinal failure-associated liver disease (IFALD). (A) clinical symptoms, (B) disease triggers, (C) treatment…
Overview of intestinal failure-associated liver disease (IFALD). (A) clinical symptoms, (B) disease triggers, (C) treatment. https://t.co/CNDhJR6VSW https://t.co/OglP4aZbiY
RT @heniek_htw: Molecular mechanisms underlying hepatoprotective activity of #lutein in the context of intestinal failure-associated #liver…
Molecular mechanisms underlying hepatoprotective activity of #lutein in the context of intestinal failure-associated #liver disease https://t.co/ATPAPSk0Mk https://t.co/INNNtsOqWx
RT @heniek_htw: #Natural bioactive compounds – the promising candidates for the treatment of intestinal failure-associated #liver disease…
RT @heniek_htw: #Natural bioactive compounds – the promising candidates for the treatment of intestinal failure-associated #liver disease…
RT @heniek_htw: #Natural bioactive compounds – the promising candidates for the treatment of intestinal failure-associated #liver disease…
#Natural bioactive compounds – the promising candidates for the treatment of intestinal failure-associated #liver disease
RT @ToxSci: #ContemporaryReview of intestinal failure-associated liver disease (IFALD). #FreeToRead https://t.co/2nseyhvbto
#ContemporaryReview of intestinal failure-associated liver disease (IFALD). #FreeToRead https://t.co/2nseyhvbto
RT @ASPEN_nutrition: Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screenin…
RT @ASPEN_nutrition: Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screenin…
RT @ASPEN_nutrition: Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screenin…
RT @ASPEN_nutrition: Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screenin…
RT @ASPEN_nutrition: Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screenin…
RT @ASPEN_nutrition: Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screenin…
Access the new article in #NCP early view: Intestinal failure–associated liver disease: Current challenges in screening, diagnosis, and parenteral nutrition considerations. https://t.co/qegxtuaHVV
$TARA had previously been pursuing an indication in intestinal failure-associated liver disease and following feedback from FDA, will now pursue a broader indication.
.@YsiosCapital NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) https://t.co/Duup27TjaR https://t.co/9d82juZqcO
NorthSea Therapeutics starts Phase 2A study of Orziloben (NST-6179) for Intestinal Failure-Associated Liver Disease (IFALD). More Info: https://t.co/xqIhDoFJm2 $XBI $IBB $XPH $PPH https://t.co/30SOrD247o
NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD) https://t.co/lJwr45IPAU https://t.co/WgFfPOYrQI
Inflammation drives pathogenesis of early intestinal failure-associated liver disease https://t.co/6lbNzpNEtt https://t.co/hcTFRl0gag
Dr. Ajay will be speaking on "Novel Biomarkers for Intestinal Failure Associated Liver Disease", at #MEAPEN2024. Register now at discounted Pre-Registration rates! https://t.co/BI9FlGHoGZ #meapen #nutrition #health #parenteralnutrition #enteralnutrition #clinicalnutrition
RT @jpedsurg: RNA-sequencing identifies novel transcriptomic signatures in intestinal failure-associated liver disease https://t.co/N0iuhbG…
RNA-sequencing identifies novel transcriptomic signatures in intestinal failure-associated liver disease https://t.co/N0iuhbGnuv #SoMe4PedSurg #jpedsurg
RT @jpedsurg: RNA-sequencing identifies novel transcriptomic signatures in intestinal failure-associated liver disease https://t.co/N0iuhbG…
RT @jpedsurg: RNA-sequencing identifies novel transcriptomic signatures in intestinal failure-associated liver disease https://t.co/N0iuhbG…
RNA-sequencing identifies novel transcriptomic signatures in intestinal failure-associated liver disease https://t.co/N0iuhbGnuv #SoMe4PedSurg #jpedsurg
Dr Shahd Ahmed from @uhbtrust giving an enthusiastic presentation on a case of regression of intestinal failure associated liver disease by altering parenteral nutrition regime https://t.co/aiTRedHGwe
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease - https://t.co/XC54mp05Bv
NorthSea Therapeutics gets FDA Rare Pediatric Disease Designation for SEFA-6179, treating Intestinal Failure-Associated Liver Disease. More Info: https://t.co/s2g7MglXA1 $XBI $IBB $XPH $PPH https://t.co/BI7h4WABq5
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease Read more here: https://t.co/x41FfJm5Fy #IFALD #NASH
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease https://t.co/Vqdl7oIdyb https://t.co/ofGulsz3XH
The gut microbiome and intestinal failure-associated liver disease https://t.co/SqhsFvNgLK
The gut microbiome and intestinal failure-associated liver disease - PubMed: Intestinal failure-associated liver disease (IFALD) is a common hepatobiliary complication resulting from long-term parenteral nutrition (PN) in patients with… #cdiff #cdi #fmt https://t.co/diHTjCUoZl
The gut microbiome and intestinal failure-associated liver disease https://t.co/Gram1IUzDK
The gut microbiome and intestinal failure-associated liver disease https://t.co/leb7Wz3tOt
Abnormal distribution of fat tissue and its association with intestinal failure associated liver disease (IFALD) in children and adolescents with long-time parenteral nutrition support: A case control study https://t.co/wZR06fQj4h
Abnormal distribution of fat tissue and its association with intestinal failure associated liver disease (IFALD) in children and adolescents with long-time parenteral nutrition support: A case control study https://t.co/zlhZkLztCr
RT @JPGNonline: .@alex_s_hudson et al studied impacts on intestinal failure associated liver disease (#IFALD) and growth after transition t…
.@alex_s_hudson et al studied impacts on intestinal failure associated liver disease (#IFALD) and growth after transition to a composite lipid emulsion, finding:
@angryhacademic In fairness, intestinal failure-associated liver disease is quite a focus for research, but the attention seems to focus on which lipid preparation is best in long-term parenteral nutrition. Sounds like choline needs some serious attention.
RT @Reports_MDPI:
We are pleased to inform you that the article "Improvement in Intestinal-Failure-Associated Liver Disease by Using Parenteral Fish Oil as Monotherapy: Case-Based Review of the Literature" has been published in Reports Website: https://t.co/2q3syJyWQc
IV Choline Chloride for intestinal failure-associated liver disease (IFALD) https://t.co/XF5ZDL7iMF
AMSDottorato: https://t.co/BZVGEO2lNF Intestinal microbiome in chronic intestinal failure and associations with intestinal failure associated liver disease
RT @ASPEN_nutrition: New and open access article in #JPEN: Lipid strategies to prevent intestinal failure–associated liver disease in neona…
RT @ASPEN_nutrition: New and open access article in #JPEN: Lipid strategies to prevent intestinal failure–associated liver disease in neona…
RT @ASPEN_nutrition: New and open access article in #JPEN: Lipid strategies to prevent intestinal failure–associated liver disease in neona…
RT @ASPEN_nutrition: New and open access article in #JPEN: Lipid strategies to prevent intestinal failure–associated liver disease in neona…
New and open access article in #JPEN: Lipid strategies to prevent intestinal failure–associated liver disease in neonates: A pilot trial. https://t.co/i0dAA3hBpH
Emerging role of regulated cell death in intestinal failure-associated liver disease https://t.co/0XKcASnwwd https://t.co/aQYCMv2IsD
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
RT @BAPENUK: Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
Last month, BIFA published Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD)
⭐️ Do you manage patients on long-term parenteral nutrition? You will be interested in this recent guidance on Intestinal Failure Associated Liver Disease (IFALD).
RT @BAPENUK: BIFA Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD) are now available on ou…
RT @BAPENUK: BIFA Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD) are now available on ou…
RT @BAPENUK: BIFA Guidelines on the Diagnosis and Management of Intestinal Failure Associated Liver Disease (IFALD) are now available on ou…
Intestinal failure -associated liver disease reversed in 6 months by fish oil #pediatrics #children medicalnewstoday.com/releases/26483…